SCHEMBL4025148

SCHEMBL4025148

O=C(O)/C=C/C=C(/c1ccc(OC2CSC2)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.51
ALDH1A1 P00352 5/20 0.51
SENP8 Q96LD8 3/20 0.51
SENP6 Q9GZR1 3/20 0.51
CASP3 P42574 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 7/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
SENP7 Q9BQF6 1/20 0.45
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
EPHX2 P34913 1/20 0.41
TEAD1 P28347 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025153 1.00 LMNA (0.51) LMNAALDH1A1SENP8SENP6CASP3
SCHEMBL4025146 1.00 LMNA (0.51) LMNAALDH1A1SENP8SENP6CASP3
SCHEMBL3948188 0.90 EPHX2 (0.51) EPHX2TEAD1CYP1A1CYP1B1ADRB2
SCHEMBL3948185 0.90 EPHX2 (0.51) EPHX2TEAD1CYP1A1CYP1B1ADRB2
SCHEMBL3937008 0.87 PARP10 (0.49) LMNAALDH1A1NPC1RAB9AEPHX2
SCHEMBL3937004 0.87 PARP10 (0.49) LMNAALDH1A1NPC1RAB9AEPHX2
SCHEMBL4205850 0.86 EPHX2 (0.41) LMNAALDH1A1SENP8SENP6CASP3
SCHEMBL4205845 0.86 EPHX2 (0.41) LMNAALDH1A1SENP8SENP6CASP3
SCHEMBL4205841 0.86 EPHX2 (0.41) LMNAALDH1A1SENP8SENP6CASP3
SCHEMBL3946996 0.84 EPHX2 (0.44) EPHX2TEAD1CYP1A1CYP1B1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 LMNA 3654/4885ALDH1A1 1143/4885SENP8 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.